Correction: Mesoporous multimetallic PdPtBi nanozymes target redox imbalance and glutamine deprivation for immuno-chemodynamic therapy

Correction: Journal of Nanobiotechnology (2025) 23:762

10.1186/s12951-025-03856-3

Due to software issues the flow cytometry scale in Fig. 6k is not aligned at the same level. Furthermore, the group labels for Fig. 6d, k, m, and o were previously omitted and have now been correctly relabeled.

Fig. 6.

Anti-metastasis effects and immune activation mechanism of PPB in vivo. (a) Scheme of the immune-mechanism of tumor killing effect. (b) Scheme against primary and distant tumor growth in bilateral Hepa 1–6 tumor-bearing mice. (c) Bioluminescence images of both the primary and distant Hepa 1–6 luc tumors on the 14th day. (d,e) The individual (d) and average (e) tumor volumes of the untreatment side in different groups (n=5). (f,g) Weight of the treatment side (f) and untreatment side tumor (g) after excision (n=5). (h-j) The expression level of IL-2 (h), TNF-α (i), IL-10 (j) in the peripheral blood of various different groups (n=3). (k-p) FCM and their statistical data of CD25⁺ Foxp3⁺ in CD4+ T cells (k,l), GZMB⁺ in CD8⁺ T cells (m,n) and IFN-γ⁺ in CD8⁺ T cells (o,p) in the PBMCs. (n=3). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001. Groups are assigned to be G1: Control; G2: US; G3: PP; G4: PP+US; G5: PPB; G6: PPB+US

In this article Fig. 6 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the old incorrect and correct versions are displayed below.

Fig. 6.

Anti-metastasis effects and immune activation mechanism of PPB in vivo. (a) Scheme of the immune-mechanism of tumor killing effect. (b) Scheme against primary and distant tumor growth in bilateral Hepa 1–6 tumor-bearing mice. (c) Bioluminescence images of both the primary and distant Hepa 1–6 luc tumors on the 14th day. (d,e) The individual (d) and average (e) tumor volumes of the untreatment side in different groups (n=5). (f,g) Weight of the treatment side (f) and untreatment side tumor (g) after excision (n=5). (h-j) The expression level of IL-2 (h), TNF-α (i), IL-10 (j) in the peripheral blood of various different groups (n=3). (k-p) FCM and their statistical data of CD25⁺ Foxp3⁺ in CD4+ T cells (k,l), GZMB⁺ in CD8⁺ T cells (m,n) and IFN-γ⁺ in CD8⁺ T cells (o,p) in the PBMCs. (n=3). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001. Groups are assigned to be G1: Control; G2: US; G3: PP; G4: PP+US; G5: PPB; G6: PPB+US

Incorrect Fig. 6:

Correct Fig. 6:

The original article has been corrected.